Risk behaviors of 15–21 year olds in Mexico lead to a high prevalence of sexually transmitted infections: results of a survey in disadvantaged urban areas

BACKGROUND: Due to the fact that adolescents are more likely to participate in high-risk behaviors, this sector of the population is particularly vulnerable to contracting sexually transmitted infections (STIs) and resultant health problems. METHODS: A survey was carried out among adolescents from poor homes in 204 small-urban areas of Mexico. Information was collected in relation to risk behaviors and socio-economic environment. A sub-group of the participants also provided blood and urine samples which were analyzed to detect sexually transmitted infections. RESULTS: The presence of Chlamydia was detected in nearly 8% of participants who had stated that they were sexually active (18%) and approximately 12% were positive for herpes type 2-specific antibodies. For both, a greater proportion of girls resulted positive compared to boys. The presence of these biological outcomes of sexual risk behavior was associated with other risk behaviors (smoking), but not with self-reported indicators of protected sex (reported use of condom during most recent sexual activity). CONCLUSION: The results presented in this study show a startlingly high prevalence of HSV-2 among sexually active Mexican adolescents in poor urban areas, suggesting that this group has participated to a great extent in risky sexual practices. The relationships between socioeconomic environment and adolescent risk behavior need to be better understood if we are to design preventive interventions that modify the determinants of risk behaviors

Mathematical modeling of microRNA-mediated mechanisms of translation repression

MicroRNAs can affect the protein translation using nine mechanistically different mechanisms, including repression of initiation and degradation of the transcript. There is a hot debate in the current literature about which mechanism and in which situations has a dominant role in living cells. The worst, same experimental systems dealing with the same pairs of mRNA and miRNA can provide ambiguous evidences about which is the actual mechanism of translation repression observed in the experiment. We start with reviewing the current knowledge of various mechanisms of miRNA action and suggest that mathematical modeling can help resolving some of the controversial interpretations. We describe three simple mathematical models of miRNA translation that can be used as tools in interpreting the experimental data on the dynamics of protein synthesis. The most complex model developed by us includes all known mechanisms of miRNA action. It allowed us to study possible dynamical patterns corresponding to different miRNA-mediated mechanisms of translation repression and to suggest concrete recipes on determining the dominant mechanism of miRNA action in the form of kinetic signatures. Using computational experiments and systematizing existing evidences from the literature, we justify a hypothesis about co-existence of distinct miRNA-mediated mechanisms of translation repression. The actually observed mechanism will be that acting on or changing the limiting "place" of the translation process. The limiting place can vary from one experimental setting to another. This model explains the majority of existing controversies reported.Comment: 40 pages, 9 figures, 4 tables, 91 cited reference. The analysis of kinetic signatures is updated according to the new model of coupled transcription, translation and degradation, and of miRNA-based regulation of this process published recently (arXiv:1204.5941). arXiv admin note: text overlap with arXiv:0911.179

Adrenergic regulation during acute hepatic infection with Entamoeba histolytica

Oxidative stress and transcriptional pathways of nuclear factor erythroid 2-related factor 2 (Nrf2) and nuclear factor kappa-B (NF-κB) are critically involved in the etiopathology of amebic liver abscess (ALA). In this work, we studied the relationship between the adrenergic nervous system and ALA in the hamster. ALA was visible at 12 h of infection. While 6-hydroxidopamine (6-OHDA) decreased infection, propranolol (β-adrenergic blocker) treatment was associated with less extensive liver damage, and phentolamine treatment (α-adrenergic blocker) significantly reduced ALA compared to 6-OHDA and propranolol. Serum enzymatic activities of alanine aminotransferase (ALT) and γ-glutamyl transpeptidase (γ-GTP) were increased at 12 h post-infection. Chemical denervation and α and β-adrenergic blockers decreased ALT to normal levels, while 6-OHDA and propranolol showed a trend to decrease γ-GTP but phentolamine significantly reduced γ-GTP. Amebic infection increased oxidized glutathione (GSSG) and decreased both reduced glutathione (GSH) and the GSH/GSSG ratio. Propranolol and 6-OHDA showed a tendency to decrease GSSG. However, GSH, GSSG and GSH/GSSG returned to normal levels with phentolamine. Furthermore, amebic infection increased pNF-κB and interleukin-1β (IL-1β), and showed a tendency to decrease hemoxigenase-1 (HO-1), but not Nrf2. Chemical denervation showed a trend to decrease pNF-κB and IL-1β, and neither Nrf2 nor HO-1 increased significantly. In addition, NF-κB and IL-1β were attenuated by propranolol and phentolamine treatments, although phentolamine showed significant overexpression of Nrf2 and HO-1. This suggests that the adrenergic system may be involved in oxidative stress and in modulation of the Nrf2 and NF-κB pathways during ALA development

Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015

BACKGROUND: Improving survival and extending the longevity of life for all populations requires timely, robust evidence on local mortality levels and trends. The Global Burden of Disease 2015 Study (GBD 2015) provides a comprehensive assessment of all-cause and cause-specific mortality for 249 causes in 195 countries and territories from 1980 to 2015. These results informed an in-depth investigation of observed and expected mortality patterns based on sociodemographic measures. METHODS: We estimated all-cause mortality by age, sex, geography, and year using an improved analytical approach originally developed for GBD 2013 and GBD 2010. Improvements included refinements to the estimation of child and adult mortality and corresponding uncertainty, parameter selection for under-5 mortality synthesis by spatiotemporal Gaussian process regression, and sibling history data processing. We also expanded the database of vital registration, survey, and census data to 14 294 geography-year datapoints. For GBD 2015, eight causes, including Ebola virus disease, were added to the previous GBD cause list for mortality. We used six modelling approaches to assess cause-specific mortality, with the Cause of Death Ensemble Model (CODEm) generating estimates for most causes. We used a series of novel analyses to systematically quantify the drivers of trends in mortality across geographies. First, we assessed observed and expected levels and trends of cause-specific mortality as they relate to the Socio-demographic Index (SDI), a summary indicator derived from measures of income per capita, educational attainment, and fertility. Second, we examined factors affecting total mortality patterns through a series of counterfactual scenarios, testing the magnitude by which population growth, population age structures, and epidemiological changes contributed to shifts in mortality. Finally, we attributed changes in life expectancy to changes in cause of death. We documented each step of the GBD 2015 estimation processes, as well as data sources, in accordance with Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER). FINDINGS: Globally, life expectancy from birth increased from 61·7 years (95% uncertainty interval 61·4-61·9) in 1980 to 71·8 years (71·5-72·2) in 2015. Several countries in sub-Saharan Africa had very large gains in life expectancy from 2005 to 2015, rebounding from an era of exceedingly high loss of life due to HIV/AIDS. At the same time, many geographies saw life expectancy stagnate or decline, particularly for men and in countries with rising mortality from war or interpersonal violence. From 2005 to 2015, male life expectancy in Syria dropped by 11·3 years (3·7-17·4), to 62·6 years (56·5-70·2). Total deaths increased by 4·1% (2·6-5·6) from 2005 to 2015, rising to 55·8 million (54·9 million to 56·6 million) in 2015, but age-standardised death rates fell by 17·0% (15·8-18·1) during this time, underscoring changes in population growth and shifts in global age structures. The result was similar for non-communicable diseases (NCDs), with total deaths from these causes increasing by 14·1% (12·6-16·0) to 39·8 million (39·2 million to 40·5 million) in 2015, whereas age-standardised rates decreased by 13·1% (11·9-14·3). Globally, this mortality pattern emerged for several NCDs, including several types of cancer, ischaemic heart disease, cirrhosis, and Alzheimer's disease and other dementias. By contrast, both total deaths and age-standardised death rates due to communicable, maternal, neonatal, and nutritional conditions significantly declined from 2005 to 2015, gains largely attributable to decreases in mortality rates due to HIV/AIDS (42·1%, 39·1-44·6), malaria (43·1%, 34·7-51·8), neonatal preterm birth complications (29·8%, 24·8-34·9), and maternal disorders (29·1%, 19·3-37·1). Progress was slower for several causes, such as lower respiratory infections and nutritional deficiencies, whereas deaths increased for others, including dengue and drug use disorders. Age-standardised death rates due to injuries significantly declined from 2005 to 2015, yet interpersonal violence and war claimed increasingly more lives in some regions, particularly in the Middle East. In 2015, rotaviral enteritis (rotavirus) was the leading cause of under-5 deaths due to diarrhoea (146 000 deaths, 118 000-183 000) and pneumococcal pneumonia was the leading cause of under-5 deaths due to lower respiratory infections (393 000 deaths, 228 000-532 000), although pathogen-specific mortality varied by region. Globally, the effects of population growth, ageing, and changes in age-standardised death rates substantially differed by cause. Our analyses on the expected associations between cause-specific mortality and SDI show the regular shifts in cause of death composition and population age structure with rising SDI. Country patterns of premature mortality (measured as years o

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015

Background: The Global Burden of Diseases, Injuries, and Risk Factors Study 2015 provides an up-to-date synthesis of the evidence for risk factor exposure and the attributable burden of disease. By providing national and subnational assessments spanning the past 25 years, this study can inform debates on the importance of addressing risks in context. Methods: We used the comparative risk assessment framework developed for previous iterations of the Global Burden of Disease Study to estimate attributable deaths, disability-adjusted life-years (DALYs), and trends in exposure by age group, sex, year, and geography for 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks from 1990 to 2015. This study included 388 risk-outcome pairs that met World Cancer Research Fund-defined criteria for convincing or probable evidence. We extracted relative risk and exposure estimates from randomised controlled trials, cohorts, pooled cohorts, household surveys, census data, satellite data, and other sources. We used statistical models to pool data, adjust for bias, and incorporate covariates. We developed a metric that allows comparisons of exposure across risk factors—the summary exposure value. Using the counterfactual scenario of theoretical minimum risk level, we estimated the portion of deaths and DALYs that could be attributed to a given risk. We decomposed trends in attributable burden into contributions from population growth, population age structure, risk exposure, and risk-deleted cause-specific DALY rates. We characterised risk exposure in relation to a Socio-demographic Index (SDI). Findings: Between 1990 and 2015, global exposure to unsafe sanitation, household air pollution, childhood underweight, childhood stunting, and smoking each decreased by more than 25%. Global exposure for several occupational risks, high body-mass index (BMI), and drug use increased by more than 25% over the same period. All risks jointly evaluated in 2015 accounted for 57·8% (95% CI 56·6–58·8) of global deaths and 41·2% (39·8–42·8) of DALYs. In 2015, the ten largest contributors to global DALYs among Level 3 risks were high systolic blood pressure (211·8 million [192·7 million to 231·1 million] global DALYs), smoking (148·6 million [134·2 million to 163·1 million]), high fasting plasma glucose (143·1 million [125·1 million to 163·5 million]), high BMI (120·1 million [83·8 million to 158·4 million]), childhood undernutrition (113·3 million [103·9 million to 123·4 million]), ambient particulate matter (103·1 million [90·8 million to 115·1 million]), high total cholesterol (88·7 million [74·6 million to 105·7 million]), household air pollution (85·6 million [66·7 million to 106·1 million]), alcohol use (85·0 million [77·2 million to 93·0 million]), and diets high in sodium (83·0 million [49·3 million to 127·5 million]). From 1990 to 2015, attributable DALYs declined for micronutrient deficiencies, childhood undernutrition, unsafe sanitation and water, and household air pollution; reductions in risk-deleted DALY rates rather than reductions in exposure drove these declines. Rising exposure contributed to notable increases in attributable DALYs from high BMI, high fasting plasma glucose, occupational carcinogens, and drug use. Environmental risks and childhood undernutrition declined steadily with SDI; low physical activity, high BMI, and high fasting plasma glucose increased with SDI. In 119 countries, metabolic risks, such as high BMI and fasting plasma glucose, contributed the most attributable DALYs in 2015. Regionally, smoking still ranked among the leading five risk factors for attributable DALYs in 109 countries; childhood underweight and unsafe sex remained primary drivers of early death and disability in much of sub-Saharan Africa. Interpretation: Declines in some key environmental risks have contributed to declines in critical infectious diseases. Some risks appear to be invariant to SDI. Increasing risks, including high BMI, high fasting plasma glucose, drug use, and some occupational exposures, contribute to rising burden from some conditions, but also provide opportunities for intervention. Some highly preventable risks, such as smoking, remain major causes of attributable DALYs, even as exposure is declining. Public policy makers need to pay attention to the risks that are increasingly major contributors to global burden. Funding: Bill & Melinda Gates Foundation

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

Background: The Global Burden of Disease, Injuries, and Risk Factor study 2013 (GBD 2013) is the first of a series of annual updates of the GBD. Risk factor quantification, particularly of modifiable risk factors, can help to identify emerging threats to population health and opportunities for prevention. The GBD 2013 provides a timely opportunity to update the comparative risk assessment with new data for exposure, relative risks, and evidence on the appropriate counterfactual risk distribution. Methods: Attributable deaths, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs) have been estimated for 79 risks or clusters of risks using the GBD 2010 methods. Risk-outcome pairs meeting explicit evidence criteria were assessed for 188 countries for the period 1990-2013 by age and sex using three inputs: risk exposure, relative risks, and the theoretical minimum risk exposure level (TMREL). Risks are organised into a hierarchy with blocks of behavioural, environmental and occupational, and metabolic risks at the first level of the hierarchy. The next level in the hierarchy includes nine clusters of related risks and two individual risks, with more detail provided at levels 3 and 4 of the hierarchy. Compared with GBD 2010, six new risk factors have been added: handwashing practices, occupational exposure to trichloroethylene, childhood wasting, childhood stunting, unsafe sex, and low glomerular filtration rate. For most risks, data for exposure were synthesised with a Bayesian metaregression method, DisMod-MR 2.0, or spatial-temporal Gaussian process regression. Relative risks were based on meta-regressions of published cohort and intervention studies. Attributable burden for clusters of risks and all risks combined took into account evidence on the mediation of some risks such as high body-mass index (BMI) through other risks such as high systolic blood pressure and high cholesterol. Findings: All risks combined account for 57·2% (95% uncertainty interval [UI] 55·8-58·5) of deaths and 41·6% (40·1-43·0) of DALYs. Risks quantified account for 87·9% (86·5-89·3) of cardiovascular disease DALYs, ranging to a low of 0% for neonatal disorders and neglected tropical diseases and malaria. In terms of global DALYs in 2013, six risks or clusters of risks each caused more than 5% of DALYs: dietary risks accounting for 11·3 million deaths and 241·4 million DALYs, high systolic blood pressure for 10·4 million deaths and 208·1 million DALYs, child and maternal malnutrition for 1·7 million deaths and 176·9 million DALYs, tobacco smoke for 6·1 million deaths and 143·5 million DALYs, air pollution for 5·5 million deaths and 141·5 million DALYs, and high BMI for 4·4 million deaths and 134·0 million DALYs. Risk factor patterns vary across regions and countries and with time. In sub-Saharan Africa, the leading risk factors are child and maternal malnutrition, unsafe sex, and unsafe water, sanitation, and handwashing. In women, in nearly all countries in the Americas, north Africa, and the Middle East, and in many other high-income countries, high BMI is the leading risk factor, with high systolic blood pressure as the leading risk in most of Central and Eastern Europe and south and east Asia. For men, high systolic blood pressure or tobacco use are the leading risks in nearly all high-income countries, in north Africa and the Middle East, Europe, and Asia. For men and women, unsafe sex is the leading risk in a corridor from Kenya to South Africa. Interpretation: Behavioural, environmental and occupational, and metabolic risks can explain half of global mortality and more than one-third of global DALYs providing many opportunities for prevention. Of the larger risks, the attributable burden of high BMI has increased in the past 23 years. In view of the prominence of behavioural risk factors, behavioural and social science research on interventions for these risks should be strengthened. Many prevention and primary care policy options are available now to act on key risks

Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015

Background Improving survival and extending the longevity of life for all populations requires timely, robust evidence on local mortality levels and trends. The Global Burden of Disease 2015 Study (GBD 2015) provides a comprehensive assessment of all-cause and cause-specific mortality for 249 causes in 195 countries and territories from 1980 to 2015. These results informed an in-depth investigation of observed and expected mortality patterns based on sociodemographic measures. Methods We estimated all-cause mortality by age, sex, geography, and year using an improved analytical approach originally developed for GBD 2013 and GBD 2010. Improvements included refinements to the estimation of child and adult mortality and corresponding uncertainty, parameter selection for under-5 mortality synthesis by spatiotemporal Gaussian process regression, and sibling history data processing. We also expanded the database of vital registration, survey, and census data to 14 294 geography–year datapoints. For GBD 2015, eight causes, including Ebola virus disease, were added to the previous GBD cause list for mortality. We used six modelling approaches to assess cause-specific mortality, with the Cause of Death Ensemble Model (CODEm) generating estimates for most causes. We used a series of novel analyses to systematically quantify the drivers of trends in mortality across geographies. First, we assessed observed and expected levels and trends of cause-specific mortality as they relate to the Socio-demographic Index (SDI), a summary indicator derived from measures of income per capita, educational attainment, and fertility. Second, we examined factors affecting total mortality patterns through a series of counterfactual scenarios, testing the magnitude by which population growth, population age structures, and epidemiological changes contributed to shifts in mortality. Finally, we attributed changes in life expectancy to changes in cause of death. We documented each step of the GBD 2015 estimation processes, as well as data sources, in accordance with Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER). Findings Globally, life expectancy from birth increased from 61·7 years (95% uncertainty interval 61·4–61·9) in 1980 to 71·8 years (71·5–72·2) in 2015. Several countries in sub-Saharan Africa had very large gains in life expectancy from 2005 to 2015, rebounding from an era of exceedingly high loss of life due to HIV/AIDS. At the same time, many geographies saw life expectancy stagnate or decline, particularly for men and in countries with rising mortality from war or interpersonal violence. From 2005 to 2015, male life expectancy in Syria dropped by 11·3 years (3·7–17·4), to 62·6 years (56·5–70·2). Total deaths increased by 4·1% (2·6–5·6) from 2005 to 2015, rising to 55·8 million (54·9 million to 56·6 million) in 2015, but age-standardised death rates fell by 17·0% (15·8–18·1) during this time, underscoring changes in population growth and shifts in global age structures. The result was similar for non-communicable diseases (NCDs), with total deaths from these causes increasing by 14·1% (12·6–16·0) to 39·8 million (39·2 million to 40·5 million) in 2015, whereas age-standardised rates decreased by 13·1% (11·9–14·3). Globally, this mortality pattern emerged for several NCDs, including several types of cancer, ischaemic heart disease, cirrhosis, and Alzheimer's disease and other dementias. By contrast, both total deaths and age-standardised death rates due to communicable, maternal, neonatal, and nutritional conditions significantly declined from 2005 to 2015, gains largely attributable to decreases in mortality rates due to HIV/AIDS (42·1%, 39·1–44·6), malaria (43·1%, 34·7–51·8), neonatal preterm birth complications (29·8%, 24·8–34·9), and maternal disorders (29·1%, 19·3–37·1). Progress was slower for several causes, such as lower respiratory infections and nutritional deficiencies, whereas deaths increased for others, including dengue and drug use disorders. Age-standardised death rates due to injuries significantly declined from 2005 to 2015, yet interpersonal violence and war claimed increasingly more lives in some regions, particularly in the Middle East. In 2015, rotaviral enteritis (rotavirus) was the leading cause of under-5 deaths due to diarrhoea (146 000 deaths, 118 000–183 000) and pneumococcal pneumonia was the leading cause of under-5 deaths due to lower respiratory infections (393 000 deaths, 228 000–532 000), although pathogen-specific mortality varied by region. Globally, the effects of population growth, ageing, and changes in age-standardised death rates substantially differed by cause. Our analyses on the expected associations between cause-specific mortality and SDI show the regular shifts in cause of death composition and population age structure with rising SDI. Country patterns of premature mortality (measured as years of life lost [YLLs]) and how they differ from the level expected on the basis of SDI alone revealed distinct but highly heterogeneous patterns by region and country or territory. Ischaemic heart disease, stroke, and diabetes were among the leading causes of YLLs in most regions, but in many cases, intraregional results sharply diverged for ratios of observed and expected YLLs based on SDI. Communicable, maternal, neonatal, and nutritional diseases caused the most YLLs throughout sub-Saharan Africa, with observed YLLs far exceeding expected YLLs for countries in which malaria or HIV/AIDS remained the leading causes of early death. Interpretation At the global scale, age-specific mortality has steadily improved over the past 35 years; this pattern of general progress continued in the past decade. Progress has been faster in most countries than expected on the basis of development measured by the SDI. Against this background of progress, some countries have seen falls in life expectancy, and age-standardised death rates for some causes are increasing. Despite progress in reducing age-standardised death rates, population growth and ageing mean that the number of deaths from most non-communicable causes are increasing in most countries, putting increased demands on health systems. Funding Bill & Melinda Gates Foundation

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017

Background: The Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017) includes a comprehensive assessment of incidence, prevalence, and years lived with disability (YLDs) for 354 causes in 195 countries and territories from 1990 to 2017. Previous GBD studies have shown how the decline of mortality rates from 1990 to 2016 has led to an increase in life expectancy, an ageing global population, and an expansion of the non-fatal burden of disease and injury. These studies have also shown how a substantial portion of the world's population experiences non-fatal health loss with considerable heterogeneity among different causes, locations, ages, and sexes. Ongoing objectives of the GBD study include increasing the level of estimation detail, improving analytical strategies, and increasing the amount of high-quality data. Methods: We estimated incidence and prevalence for 354 diseases and injuries and 3484 sequelae. We used an updated and extensive body of literature studies, survey data, surveillance data, inpatient admission records, outpatient visit records, and health insurance claims, and additionally used results from cause of death models to inform estimates using a total of 68 781 data sources. Newly available clinical data from India, Iran, Japan, Jordan, Nepal, China, Brazil, Norway, and Italy were incorporated, as well as updated claims data from the USA and new claims data from Taiwan (province of China) and Singapore. We used DisMod-MR 2.1, a Bayesian meta-regression tool, as the main method of estimation, ensuring consistency between rates of incidence, prevalence, remission, and cause of death for each condition. YLDs were estimated as the product of a prevalence estimate and a disability weight for health states of each mutually exclusive sequela, adjusted for comorbidity. We updated the Socio-demographic Index (SDI), a summary development indicator of income per capita, years of schooling, and total fertility rate. Additionally, we calculated differences between male and female YLDs to identify divergent trends across sexes. GBD 2017 complies with the Guidelines for Accurate and Transparent Health Estimates Reporting. Findings: Globally, for females, the causes with the greatest age-standardised prevalence were oral disorders, headache disorders, and haemoglobinopathies and haemolytic anaemias in both 1990 and 2017. For males, the causes with the greatest age-standardised prevalence were oral disorders, headache disorders, and tuberculosis including latent tuberculosis infection in both 1990 and 2017. In terms of YLDs, low back pain, headache disorders, and dietary iron deficiency were the leading Level 3 causes of YLD counts in 1990, whereas low back pain, headache disorders, and depressive disorders were the leading causes in 2017 for both sexes combined. All-cause age-standardised YLD rates decreased by 3·9% (95% uncertainty interval [UI] 3·1-4·6) from 1990 to 2017; however, the all-age YLD rate increased by 7·2% (6·0-8·4) while the total sum of global YLDs increased from 562 million (421-723) to 853 million (642-1100). The increases for males and females were similar, with increases in all-age YLD rates of 7·9% (6·6-9·2) for males and 6·5% (5·4-7·7) for females. We found significant differences between males and females in terms of age-standardised prevalence estimates for multiple causes. The causes with the greatest relative differences between sexes in 2017 included substance use disorders (3018 cases [95% UI 2782-3252] per 100 000 in males vs 1400 [1279-1524] per 100 000 in females), transport injuries (3322 [3082-3583] vs 2336 [2154-2535]), and self-harm and interpersonal violence (3265 [2943-3630] vs 5643 [5057-6302]). Interpretation: Global all-cause age-standardised YLD rates have improved only slightly over a period spanning nearly three decades. However, the magnitude of the non-fatal disease burden has expanded globally, with increasing numbers of people who have a wide spectrum of conditions. A subset of conditions has remained globally pervasive since 1990, whereas other conditions have displayed more dynamic trends, with different ages, sexes, and geographies across the globe experiencing varying burdens and trends of health loss. This study emphasises how global improvements in premature mortality for select conditions have led to older populations with complex and potentially expensive diseases, yet also highlights global achievements in certain domains of disease and injury

Assessing parallel gene histories in viral genomes

Background: The increasing abundance of sequence data has exacerbated a long known problem: gene trees and species trees for the same terminal taxa are often incongruent. Indeed, genes within a genome have not all followed the same evolutionary path due to events such as incomplete lineage sorting, horizontal gene transfer, gene duplication and deletion, or recombination. Considering conflicts between gene trees as an obstacle, numerous methods have been developed to deal with these incongruences and to reconstruct consensus evolutionary histories of species despite the heterogeneity in the history of their genes. However, inconsistencies can also be seen as a source of information about the specific evolutionary processes that have shaped genomes. Results: The goal of the approach here proposed is to exploit this conflicting information: we have compiled eleven variables describing phylogenetic relationships and evolutionary pressures and submitted them to dimensionality reduction techniques to identify genes with similar evolutionary histories. To illustrate the applicability of the method, we have chosen two viral datasets, namely papillomaviruses and Turnip mosaic virus (TuMV) isolates, largely dissimilar in genome, evolutionary distance and biology. Our method pinpoints viral genes with common evolutionary patterns. In the case of papillomaviruses, gene clusters match well our knowledge on viral biology and life cycle, illustrating the potential of our approach. For the less known TuMV, our results trigger new hypotheses about viral evolution and gene interaction. Conclusions: The approach here presented allows turning phylogenetic inconsistencies into evolutionary information, detecting gene assemblies with similar histories, and could be a powerful tool for comparative pathogenomics.IGB was funded by the disappeared Spanish Ministry for Science and Innovation (CGL2010-16713). Work in Valencia was supported by grant BFU2012-30805 from the Spanish Ministry of Economy and Competitiveness (MINECO) to SFE. BMC is the recipient of an IDIBELL PhD fellowship.Mengual-Chuliá, B.; Bedhomme, S.; Lafforgue, G.; Elena Fito, SF.; Bravo, IG. (2016). Assessing parallel gene histories in viral genomes. BMC Evolutionary Biology. 16:1-15. https://doi.org/10.1186/s12862-016-0605-4S11516Hess J, Goldman N. Addressing inter-gene heterogeneity in maximum likelihood phylogenomic analysis: Yeasts revisited. PLoS ONE. 2011;6:e22783.Salichos L, Rokas A. Inferring ancient divergences requires genes with strong phylogenetic signals. Nature. 2013;497:327–31.Zhong B, Liu L, Yan Z, Penny D. Origin of land plants using the multispecies coalescent model. Trends Plant Sci. 2013;18:492–5.Song S, Liu L, Edwards SV, Wu S. Resolving conflict in eutherian mammal phylogeny using phylogenomics and the multispecies coalescent model. Proc Natl Acad Sci U S A. 2012;109:14942–7.Nichols R. Gene trees and species trees are not the same. Trends Ecol Evol. 2001;16:358–64.Maddison WP. Gene trees in species trees. Syst Biol. 1997;46:523–36.Suh A, Smeds L, Ellegren H. The dynamics of incomplete lineage sorting across the ancient adaptive radiation of neoavian birds. PLoS Biol. 2015;13:e1002224.McBreen K, Lockhart PJ. Reconstructing reticulate evolutionary histories of plants. Trends Plant Sci. 2006;11:398–404.Dagan T, Martin W. The tree of one percent. Genome Biol. 2006;7:118.Beiko RG, Harlow TJ, Ragan MA. Highways of gene sharing in prokaryotes. Proc Natl Acad Sci U S A. 2005;102:14332–7.Cotton JA, Page RD. Going nuclear: Gene family evolution and vertebrate phylogeny reconciled. Proc Biol Sci. 2002;269:1555–61.Kuhner MK, Yamato J. Practical performance of tree comparison metrics. Syst Biol. 2015;64:205–14.Brochier C, Bapteste E, Moreira D, Philippe H. Eubacterial phylogeny based on translational apparatus proteins. Trends Genet. 2002;18:1–5.Bapteste E, Susko E, Leigh J, MacLeod D, Charlebois RL, Doolittle WF. Do orthologous gene phylogenies really support tree-thinking? BMC Evol Biol. 2005;5:33.Leigh JW, Susko E, Baumgartner M, Roger AJ. Testing congruence in phylogenomic analysis. Syst Biol. 2008;57:104–15.Leigh JW, Schliep K, Lopez P, Bapteste E. Let them fall where they may: Congruence analysis in massive phylogenetically messy data sets. Mol Biol Evol. 2011;28:2773–85.de Vienne DM, Ollier S, Aguileta G. Phylo-mcoa: A fast and efficient method to detect outlier genes and species in phylogenomics using multiple co-inertia analysis. Mol Biol Evol. 2012;29:1587–98.Wang S, Luo X, Wei W, Zheng Y, Dou Y, Cai X. Calculation of evolutionary correlation between individual genes and full-length genome: A method useful for choosing phylogenetic markers for molecular epidemiology. PLoS ONE. 2013;8:e81106.Salichos L, Stamatakis A, Rokas A. Novel information theory-based measures for quantifying incongruence among phylogenetic trees. Mol Biol Evol. 2014;31:1261–71.Weyenberg G, Huggins PM, Schardl CL, Howe DK, Yoshida R. Kdetrees: Non-parametric estimation of phylogenetic tree distributions. Bioinformatics. 2014;30:2280–7.de Queiroz A. For consensus (sometimes). Syst Biol. 1993;42:368–72.Miyamoto MM, Fitch WM. Testing the covarion hypothesis of molecular evolution. Mol Biol Evol. 1995;12:503–13.Sanderson MJ, Purvis A, Henze C. Phylogenetic supertrees: Assembling the trees of life. Trends Ecol Evol. 1998;13:105–9.Bininda-Emonds ORP. Phylogenetic supertrees: Combining information to reveal the tree of life. Comput Biol. Dordrecht (The Netherlands): Kluwer Academic Publishers; 2004.Creevey CJ, Fitzpatrick DA, Philip GK, Kinsella RJ, O’Connell MJ, Pentony MM, et al. Does a tree-like phylogeny only exist at the tips in the prokaryotes? Proc Biol Sci. 2004;271:2551–8.Pisani D, Cotton JA, McInerney JO. Supertrees disentangle the chimerical origin of eukaryotic genomes. Mol Biol Evol. 2007;24:1752–60.Ane C, Larget B, Baum DA, Smith SD, Rokas A. Bayesian estimation of concordance among gene trees. Mol Biol Evol. 2007;24:412–26.Gordon AD. A measure of the agreement between rankings. Biometrika. 1979;66:7–15.de Vienne DM, Giraud T, Martin OC. A congruence index for testing topological similarity between trees. Bioinformatics. 2007;23:3119–24.Suchard MA, Weiss RE, Sinsheimer JS, Dorman KS, Patel M, McCabe ERB. Evolutionary similarity among genes. J Am Stat Assoc. 2003;98:653–62.Edwards SV, Liu L, Pearl DK. High-resolution species trees without concatenation. Proc Natl Acad Sci U S A. 2007;104:5936–41.Liu L, Pearl DK. Species trees from gene trees: Reconstructing bayesian posterior distributions of a species phylogeny using estimated gene tree distributions. Syst Biol. 2007;56:504–14.Liu L, Pearl DK, Brumfield RT, Edwards SV. Estimating species trees using multiple-allele DNA sequence data. Evolution. 2008;62:2080–91.Levasseur C, Lapointe FJ. War and peace in phylogenetics: A rejoinder on total evidence and consensus. Syst Biol. 2001;50:881–91.de Queiroz A, Gatesy J. The supermatrix approach to systematics. Trends Ecol Evol. 2007;22:34–41.Huson DH, Bryant D. Application of phylogenetic networks in evolutionary studies. Mol Biol Evol. 2006;23:254–67.Layeghifard M, Peres-Neto PR, Makarenkov V. Inferring explicit weighted consensus networks to represent alternative evolutionary histories. BMC Evol Biol. 2013;13:274.Stockham C, Wang LS, Warnow T. Statistically based postprocessing of phylogenetic analysis by clustering. Bioinformatics. 2002;18 Suppl 1:S285–93.Bonnard C, Berry V, Lartillot N. Multipolar consensus for phylogenetic trees. Syst Biol. 2006;55:837–43.Guenoche A. Multiple consensus trees: A method to separate divergent genes. BMC Bioinformatics. 2013;14:46.Duggal R, Cuconati A, Gromeier M, Wimmer E. Genetic recombination of poliovirus in a cell-free system. Proc Natl Acad Sci U S A. 1997;94:13786–91.Reiter J, Perez-Vilaro G, Scheller N, Mina LB, Diez J, Meyerhans A. Hepatitis c virus rna recombination in cell culture. J Hepatol. 2011;55:777–83.Desbiez C, Lecoq H. Evidence for multiple intraspecific recombinants in natural populations of watermelon mosaic virus (wmv, potyvirus). Arch Virol. 2008;153:1749–54.Larsen RC, Miklas PN, Druffel KL, Wyatt SD. Nl-3 k strain is a stable and naturally occurring interspecific recombinant derived from bean common mosaic necrosis virus and bean common mosaic virus. Phytopathology. 2005;95:1037–42.Valli A, Lopez-Moya JJ, Garcia JA. Recombination and gene duplication in the evolutionary diversification of p1 proteins in the family potyviridae. J Gen Virol. 2007;88:1016–28.Gottschling M, Bravo IG, Schulz E, Bracho MA, Deaville R, Jepson PD, et al. Modular organizations of novel cetacean papillomaviruses. Mol Phylogenet Evol. 2011;59:34–42.Woolford L, Rector A, Van Ranst M, Ducki A, Bennett MD, Nicholls PK, et al. A novel virus detected in papillomas and carcinomas of the endangered western barred bandicoot (perameles bougainville) exhibits genomic features of both the papillomaviridae and polyomaviridae. J Virol. 2007;81:13280–90.Chen X, Zhang Q, He C, Zhang L, Li J, Zhang W, et al. Recombination and natural selection in hepatitis e virus genotypes. J Med Virol. 2012;84:1396–407.Cadar D, Csagola A, Kiss T, Tuboly T. Capsid protein evolution and comparative phylogeny of novel porcine parvoviruses. Mol Phylogenet Evol. 2013;66:243–53.Smith LM, McWhorter AR, Shellam GR, Redwood AJ. The genome of murine cytomegalovirus is shaped by purifying selection and extensive recombination. Virology. 2013;435:258–68.Münk C, Willemsen A, Bravo IG. An ancient history of gene duplications, fusions and losses in the evolution of apobec3 mutators in mammals. BMC Evol Biol. 2012;12:71.Daugherty MD, Malik HS. Rules of engagement: Molecular insights from host-virus arms races. Annu Rev Genet. 2012;46:677–700.Edgar RC. Muscle: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004;32:1792–7.Castresana J. Selection of conserved blocks from multiple alignments for their use in phylogenetic analysis. Mol Biol Evol. 2000;17:540–52.Stamatakis A, Ludwig T, Meier H. Raxml-iii: A fast program for maximum likelihood-based inference of large phylogenetic trees. Bioinformatics. 2005;21:456–63.Soria-Carrasco V, Talavera G, Igea J, Castresana J. The k tree score: Quantification of differences in the relative branch length and topology of phylogenetic trees. Bioinformatics. 2007;23:2954–6.Stern A, Doron-Faigenboim A, Erez E, Martz E, Bacharach E, Pupko T. Selecton 2007: Advanced models for detecting positive and purifying selection using a bayesian inference approach. Nucleic Acids Res. 2007;35:W506–11.Doron-Faigenboim A, Pupko T. A combined empirical and mechanistic codon model. Mol Biol Evol. 2007;24:388–97.Swanson WJ, Nielsen R, Yang Q. Pervasive adaptive evolution in mammalian fertilization proteins. Mol Biol Evol. 2003;20:18–20.Shukla DD, Ward CW, Brunt AA. The potyviridae. Wallingford (UK): CABI; 1994.Chung BY, Miller WA, Atkins JF, Firth AE. An overlapping essential gene in the potyviridae. Proc Natl Acad Sci U S A. 2008;105:5897–902.Tan Z, Wada Y, Chen J, Ohshima K. Inter- and intralineage recombinants are common in natural populations of turnip mosaic virus. J Gen Virol. 2004;85:2683–96.Bravo IG, de Sanjose S, Gottschling M. The clinical importance of understanding the evolution of papillomaviruses. Trends Microbiol. 2010;18:432–8.Klingelhutz AJ, Roman A. Cellular transformation by human papillomaviruses: Lessons learned by comparing high- and low-risk viruses. Virology. 2012;424:77–98.Bravo IG, Alonso A. Mucosal human papillomaviruses encode four different e5 proteins whose chemistry and phylogeny correlate with malignant or benign growth. J Virol. 2004;78:13613–26.Garcia-Vallve S, Alonso A, Bravo IG. Papillomaviruses: Different genes have different histories. Trends Microbiol. 2005;13:514–21.Bravo IG, Felez-Sanchez M. Papillomaviruses: Viral evolution, cancer and evolutionary medicine. Evol Med Public Health. 2015;2015:32–51.Aleman-Verdaguer ME, Goudou-Urbino C, Dubern J, Beachy RN, Fauquet C. Analysis of the sequence diversity of the p1, hc, p3, nib and cp genomic regions of several yam mosaic potyvirus isolates: Implications for the intraspecies molecular diversity of potyviruses. J Gen Virol. 1997;78(Pt 6):1253–64.Sakai J, Mori M, Morishita T, Tanaka M, Hanada K, Usugi T, et al. Complete nucleotide sequence and genome organization of sweet potato feathery mottle virus (s strain) genomic rna: The large coding region of the p1 gene. Arch Virol. 1997;142:1553–62.Tordo VM, Chachulska AM, Fakhfakh H, Le Romancer M, Robaglia C, Astier-Manifacier S. Sequence polymorphism in the 5’ntr and in the p1 coding region of potato virus y genomic rna. J Gen Virol. 1995;76(Pt 4):939–49.Verchot J, Carrington JC. Evidence that the potyvirus p1 proteinase functions in trans as an accessory factor for genome amplification. J Virol. 1995;69:3668–74.Salvador B, Saenz P, Yanguez E, Quiot JB, Quiot L, Delgadillo MO, et al. Host-specific effect of p1 exchange between two potyviruses. Mol Plant Pathol. 2008;9:147–55.Desbiez C, Lecoq H. The nucleotide sequence of watermelon mosaic virus (wmv, potyvirus) reveals interspecific recombination between two related potyviruses in the 5’ part of the genome. Arch Virol. 2004;149:1619–32.Majer E, Salvador Z, Zwart MP, Willemsen A, Elena SF, Daros JA. Relocation of the nib gene in the tobacco etch potyvirus genome. J Virol. 2014;88:4586–90.Pasin F, Simon-Mateo C, Garcia JA. The hypervariable amino-terminus of p1 protease modulates potyviral replication and host defense responses. PLoS Pathog. 2014;10:e1003985.Lopez-Lastra M, Rivas A, Barria MI. Protein synthesis in eukaryotes: The growing biological relevance of cap-independent translation initiation. Biol Res. 2005;38:121–46.Kang ST, Wang HC, Yang YT, Kou GH, Lo CF. The DNA virus white spot syndrome virus uses an internal ribosome entry site for translation of the highly expressed nonstructural protein icp35. J Virol. 2013;87:13263–78.Dolja VV, Haldeman-Cahill R, Montgomery AE, Vandenbosch KA, Carrington JC. Capsid protein determinants involved in cell-to-cell and long distance movement of tobacco etch potyvirus. Virology. 1995;206:1007–16.Carrington JC, Jensen PE, Schaad MC. Genetic evidence for an essential role for potyvirus ci protein in cell-to-cell movement. Plant J. 1998;14:393–400.Wei T, Zhang C, Hong J, Xiong R, Kasschau KD, Zhou X, et al. Formation of complexes at plasmodesmata for potyvirus intercellular movement is mediated by the viral protein p3n-pipo. PLoS Pathog. 2010;6:e1000962.Felez-Sanchez M, Trosemeier JH, Bedhomme S, Gonzalez-Bravo MI, Kamp C, Bravo IG. Cancer, warts, or asymptomatic infections: Clinical presentation matches codon usage preferences in human papillomaviruses. Genome Biol Evol. 2015;7:2117–35.Doorbar J, Gallimore PH. Identification of proteins encoded by the l1 and l2 open reading frames of human papillomavirus 1a. J Virol. 1987;61:2793–9.Hughes FJ, Romanos MA. E1 protein of human papillomavirus is a DNA helicase/atpase. Nucleic Acids Res. 1993;21:5817–23.Sarafi TR, McBride AA. Domains of the bpv-1 e1 replication protein required for origin-specific DNA binding and interaction with the e2 transactivator. Virology. 1995;211:385–96.Chen G, Stenlund A. Characterization of the DNA-binding domain of the bovine papillomavirus replication initiator e1. J Virol. 1998;72:2567–76.McBride AA. Replication and partitioning of papillomavirus genomes. Adv Virus Res. 2008;72:155–205.McBride A, Myers G. The e2 proteins: An update. In: Laboratory HPLAN. Los Alamos: Myers, G., and coworkers; 1997. p. III54–99.Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus l1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A. 1992;89:12180–4.Penrose KJ, McBride AA. Proteasome-mediated degradation of the papillomavirus e2-ta protein is regulated by phosphorylation and can modulate viral genome copy number. J Virol. 2000;74:6031–8.Poddar A, Reed SC, McPhillips MG, Spindler JE, McBride AA. The human papillomavirus type 8 e2 tethering protein targets the ribosomal DNA loci of host mitotic chromosomes. J Virol. 2009;83:640–50.Lai MC, Teh BH, Tarn WY. A human papillomavirus e2 transcriptional activator. The interactions with cellular splicing factors and potential function in pre-mrna processing. J Biol Chem. 1999;274:11832–41.Zou N, Lin BY, Duan F, Lee KY, Jin G, Guan R, et al. The hinge of the human papillomavirus type 11 e2 protein contains major determinants for nuclear localization and nuclear matrix association. J Virol. 2000;74:3761–70.Steger G, Schnabel C, Schmidt HM. The hinge region of the human papillomavirus type 8 e2 protein activates the human p21(waf1/cip1) promoter via interaction with sp1. J Gen Virol. 2002;83:503–10.Hughes AL, Hughes MA. Patterns of nucleotide difference in overlapping and non-overlapping reading frames of papillomavirus genomes. Virus Res. 2005;113:81–8.Ahola H, Bergman P, Strom AC, Moreno-Lopez J, Pettersson U. Organization and expression of the transforming region from the european elk papillomavirus (eepv). Gene. 1986;50:195–205.Chen Z, Schiffman M, Herrero R, Desalle R, Burk RD. Human papillomavirus (hpv) types 101 and 103 isolated from cervicovaginal cells lack an e6 open reading frame (orf) and are related to gamma-papillomaviruses. Virology. 2007;360:447–53.Nobre RJ, Herraez-Hernandez E, Fei JW, Langbein L, Kaden S, Grone HJ, et al. E7 oncoprotein of novel human papillomavirus type 108 lacking the e6 gene induces dysplasia in organotypic keratinocyte cultures. J Virol. 2009;83:2907–16.Stevens H, Rector A, Bertelsen MF, Leifsson PS, Van Ranst M. Novel papillomavirus isolated from the oral mucosa of a polar bear does not cluster with other papillomaviruses of carnivores. Vet Microbiol. 2008;129:108–16.Stevens H, Rector A, Van Der Kroght K, Van Ranst M. Isolation and cloning of two variant papillomaviruses from domestic pigs: Sus scrofa papillomaviruses type 1 variants a and b. J Gen Virol. 2008;89:2475–81.Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 e7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;243:934–7.Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 e6 proteins with p53. Science. 1990;248:76–9.Huibregtse JM, Scheffner M, Howley PM. A cellular protein mediates association of p53 with the e6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 1991;10:4129–35.Hartley KA, Alexander KA. Human tata binding protein inhibits human papillomavirus type 11 DNA replication by antagonizing e1-e2 protein complex formation on the viral origin of replication. J Virol. 2002;76:5014–23.Ilves I, Kadaja M, Ustav M. Two separate replication modes of the bovine papillomavirus bpv1 origin of replication that have different sensitivity to p53. Virus Res. 2003;96:75–84.Narahari J, Fisk JC, Melendy T, Roman A. Interactions of the cellular ccaat displacement protein and human papillomavirus e2 protein with the viral origin of replication can regulate DNA replication. Virology. 2006;350:302–11.Barrow-Laing L, Chen W, Roman A. Low- and high-risk human papillomavirus e7 proteins regulate p130 differently. Virology. 2010;400:233–9.White EA, Sowa ME, Tan MJ, Jeudy S, Hayes SD, Santha S, et al. Systematic identification of interactions between host cell proteins and e7 oncoproteins from diverse human papillomaviruses. Proc Natl Acad Sci U S A. 2012;109:E260–7.Nomine Y, Masson M, Charbonnier S, Zanier K, Ristriani T, Deryckere F, et al. Structural and functional analysis of e6 oncoprotein: Insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol Cell. 2006;21:665–78.Zanier K, ould M’hamed ould Sidi A, Boulade-Ladame C, Rybin V, Chappelle A, Atkinson A, et al. Solution structure analysis of the hpv16 e6 oncoprotein reveals a self-association mechanism required for e6-mediated degradation of p53. Structure. 2012;20:604–17.Briddon RW, Patil BL, Bagewadi B, Nawaz-ul-Rehman MS, Fauquet CM. Distinct evolutionary histories of the DNA-a and DNA-b components of bipartite begomoviruses. BMC Evol Biol. 2010;10:97.Chen JM, Sun YX, Chen JW, Liu S, Yu JM, Shen CJ, et al. Panorama phylogenetic diversity and distribution of type a influenza viruses based on their six internal gene sequences. J Virol. 2009;6:137